Adagrasib in Non‑Small‑Cell Lung Cancer Harboring a KRAS(G12C) Mutation
In patients with previously treated KRASG12C‑mutated NSCLC, adagrasib showed clinical efficacy without new safety signals, demonstrating durable responses and manageable toxicity in a phase 2 registrational study.
This phase 2, open‑label, multicenter study evaluated adagrasib (600 mg orally twice daily) in 116 patients with KRASG12C‑mutated, platinum‑pretreated NSCLC. Among 112 patients with measurable disease, 42.9 % attained confirmed objective responses; median duration of response was 8.5 months, median progression‑free survival 6.5 months, and median overall survival 12.6 months. Intracranial objective response rate in patients with stable CNS metastases was 33.3 %. Treatment‑related adverse events occurred in 97.4 % of patients, with grade ≥ 3 toxicity in 44.8 %. The safety profile was acceptable and no new signals emerged.
KRAS G12C is an oncogenic driver in a subset of NSCLC patients for whom targeted therapy options are limited; adagrasib provides a novel, orally bioavailable inhibitor that achieves meaningful clinical benefit and could redefine post‑platinum, post‑immunotherapy management.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT